Trial Status
Open for enrollment

What is the Purpose of this Study?
To evaluate the effectivness of IVIg in patients with MG in terms of improvement in MG symptoms as compared to placebo.

Who is Eligible to Participate?
Patients between the ages of 18 and 85 with a diagnosis of MG. Patients who ONLY have a history of Ocular MG are not eligible. No IVIg treatment within the last 3 months. Patients will also have to meet all inclusion criteria, which will be explained in greater detail by the study coordinator.

What is involved in this Study?
Patients will be given IVIG or placebo treatment every 3 weeks for 24 weeks. Patients will complete follow up appointments every 3 weeks for 18 months.

How long is the Study?
This study will be approximately 18 months long.

For more information contact:
Lynette McKinney, MSCS, CRC, Study Coordinator at 602-358-2271 or lmckinney@pnal.net